LLY

999.26

-0.72%↓

JNJ

228.04

-0.74%↓

ABBV

209.97

-0.24%↓

UNH

391

-2.31%↓

AZN

181.67

-1.91%↓

LLY

999.26

-0.72%↓

JNJ

228.04

-0.74%↓

ABBV

209.97

-0.24%↓

UNH

391

-2.31%↓

AZN

181.67

-1.91%↓

LLY

999.26

-0.72%↓

JNJ

228.04

-0.74%↓

ABBV

209.97

-0.24%↓

UNH

391

-2.31%↓

AZN

181.67

-1.91%↓

LLY

999.26

-0.72%↓

JNJ

228.04

-0.74%↓

ABBV

209.97

-0.24%↓

UNH

391

-2.31%↓

AZN

181.67

-1.91%↓

LLY

999.26

-0.72%↓

JNJ

228.04

-0.74%↓

ABBV

209.97

-0.24%↓

UNH

391

-2.31%↓

AZN

181.67

-1.91%↓

Начало・Списък с акции・Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals Inc

Отворен

СекторЗдравеопазване

91.31 -4.13

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

90.28

Максимум

96.34

Ключови измерители
By Trading Economics
Приходи	-8.1M -56M
Продажби	2.9M 60M
EPS	-0.83
Марж на печалбата	-92.559
Служители	414
EBITDA	-9.7M -52M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+46.86% upside

Дивиденти
By Dow Jones
Следващи печалби	4.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	124M 6B
Предишно отваряне	95.44
Предишно затваряне	91.31

Настроения в новините

By Acuity

50%

171 / 346 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

60 / 65.58 Подкрепа & съпротива

Rhythm Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

14.05.2026 г., 22:44 ч. UTC

Придобивния, сливания и поглъщания

LVMH to Sell Marc Jacobs Fashion Brand to WHP, G-III Apparel -- 2nd Update

14.05.2026 г., 22:27 ч. UTC

Придобивния, сливания и поглъщания

LVMH Selling Marc Jacobs Fashion Brand to WHP, G-III Apparel -- Update

14.05.2026 г., 22:12 ч. UTC

Печалби

Applied Materials Raises Outlook as Semiconductor Equipment Demand Grows -- 2nd Update

14.05.2026 г., 21:52 ч. UTC

Придобивния, сливания и поглъщания

LVMH to Sell Marc Jacobs

15.05.2026 г., 00:00 ч. UTC

Печалби

Honda's Never Faced a Crisis Like This -- And a Comeback Won't Be Easy -- WSJ

14.05.2026 г., 23:57 ч. UTC

Придобивния, сливания и поглъщания

Kakao: Stake Sales Aim to Secure Funds for Future Investments

14.05.2026 г., 23:56 ч. UTC

Придобивния, сливания и поглъщания

Kakao: Share Sale to Lower Kakao Investment's Stake in Dunmau to 4.03%

14.05.2026 г., 23:56 ч. UTC

Придобивния, сливания и поглъщания

Kakao: Affiliate Kakao Investment to Sell 2.3M Dunamu Shares on June 15

14.05.2026 г., 23:56 ч. UTC

Пазарно говорене

Gold Prices Rise on Strong Demand -- Market Talk

14.05.2026 г., 23:56 ч. UTC

Придобивния, сливания и поглъщания

Kakao to Sell 6.55% Stake in Crypto Exchange Operator Dunamu to Hana Financial for KRW1.003T

14.05.2026 г., 23:50 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

14.05.2026 г., 23:50 ч. UTC

Пазарно говорене

Nikkei May Rise as AI Enthusiasm Continues -- Market Talk

14.05.2026 г., 23:47 ч. UTC

Печалби

JSW Steel: Prolonged Supply-Chain Disruptions Due to Middle East Crisis Pose Risk to Growth >500228.BY

14.05.2026 г., 23:47 ч. UTC

Печалби

JSW Steel Results Supported by Higher Steel Prices, One-Off Divestment Gains >500228.BY

14.05.2026 г., 23:46 ч. UTC

Печалби

JSW Steel 4Q Net INR163.7B Vs. Net INR21.39B >500228.BY

14.05.2026 г., 23:46 ч. UTC

Печалби

JSW Steel 4Q Rev INR511.8B Vs. INR448.19B >500228.BY

14.05.2026 г., 23:28 ч. UTC

Пазарно говорене

New Zealand's Economy Faltering Amid Shocks -- Market Talk

14.05.2026 г., 23:00 ч. UTC

Пазарно говорене

Australia's One Nation Party Leads In The Polls -- Market Talk

14.05.2026 г., 22:46 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

14.05.2026 г., 22:46 ч. UTC

Пазарно говорене

Court Decision 'Negative But Balanced' for Coles -- Market Talk

14.05.2026 г., 22:46 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

14.05.2026 г., 22:35 ч. UTC

Пазарно говорене

Fed's Warsh Talks Big Game; Will Focus On Credibility First -- Market Talk

14.05.2026 г., 22:11 ч. UTC

Придобивния, сливания и поглъщания

LVMH Agrees to Sell Marc Jacobs -- WSJ

14.05.2026 г., 22:06 ч. UTC

Пазарно говорене

Applied Materials Gets Improved Visibility into Customer Orders -- Market Talk

14.05.2026 г., 22:04 ч. UTC

Печалби

Thai Beverage Results Supported by Higher Contributions From Spritis Business >Y92.SG

14.05.2026 г., 22:04 ч. UTC

Печалби

Thai Beverage 2Q Net THB7.37B Vs. Net THB6.74B >Y92.SG

14.05.2026 г., 22:04 ч. UTC

Печалби

Thai Beverage 2Q Rev THB86.52B Vs. THB85.35B >Y92.SG

14.05.2026 г., 22:00 ч. UTC

Печалби

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

14.05.2026 г., 21:55 ч. UTC

Печалби

Nu Holdings 1Q EPS 18c >NU

14.05.2026 г., 21:55 ч. UTC

Печалби

Nu Holdings 1Q Rev $4.97B >NU

Сравнение с други в отрасъла

Ценова промяна

Rhythm Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

46.86% нагоре

12-месечна прогноза

Среден 137.64 USD 46.86%

Висок 158 USD

Нисък 105 USD

Според 14 анализатори от Wall Street, предложили 12-месечна ценова цел за Rhythm Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

14 ratings

Купи

Задържане

Продай

Според 14 анализатори, дали борсови рейтинги на Rhythm Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

60 / 65.58Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bullish.

Recent bullish events outweigh bearish events.

Настроение

By Acuity

171 / 346 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.